Table 1.
Riskscore – risk factors and their weight
| 1p (ie, 5-fold increased risk) |
| Heterozygous FV Leiden |
| Heterozygous protrombin gene mutation |
| Overweight (>28 in BMI in early pregnancy) |
| Cesarean section |
| Familial thrombosis less than 60 years |
| Maternal age >40 years |
| Preeclampsia |
| Abruptio placenta |
| Other large risk factor |
| 2p (ie, 25-fold increased risk) |
| Protein S-deficiency |
| Protein C-deficiency |
| Immobilization (ie, plaster-treatment, strict bed rest ≥1 week, or over-stimulation syndrome)1 |
| Lupus antikoagulans2 |
| Cardiolipin antibodies2 |
| 3p (ie, 125-fold increased risk) |
| Homozygous FV Leiden |
| Homozygous prothrombin gene mutation |
| ≥4p High risk (10% absolute risk of VTE in relation to pregnancy) |
| Prior venous thromboembolic event (VTE) |
| Antiphospholipid syndrome (APS) without prior VTE2 |
| Very high risk (>15% absolute risk of VTE)3 |
| Mechanical heart valves |
| Continuous warfarin prophylaxis |
| Antithrombin deficiency |
| Repeated thromboses |
| APS with prior VTE2 |
1
At immobilization during pregnant short term thromboprophylaxis is recommended, ie, during the risk period.
2
Women with APS, lupus anticoagulants, or anticardiolipin antibodies are also recommended low-dose ASA 75mg/d.
3Women with “very high risk” are recommended high dose prophylaxis (ie, twice daily with anti factor X activity remaining before next injection).